| Literature DB >> 20440387 |
Abstract
Entities:
Year: 2007 PMID: 20440387 PMCID: PMC2859735
Source DB: PubMed Journal: Cal J Emerg Med ISSN: 1948-3384
Pharmacology of Phencyclidine (PCP) in the central nervous system
|
PCP has contrary actions on the glutamate
transmission, explaining its different effects
-Inhibits the ion flux at the NMDA glutamate
receptor -Increases glutamate transmission at non-NMDA
receptors (G-protein mediated response) Inhibits the GABAergic output Decreases DA and NE uptake Increases the DA and NE levels by stimulating the enzyme tyrosine hydroxylase |
| GABA: γ - aminobutyric acid |
| NMDA: N-methyl D-aspartate |
| DA: dopamine |
| NA: norepinephrine |
Modified after Williams and Keyes (Williams, 2001 #16) and Brust (Brust, 1999 #6)
Neuropsychiatric and clinical effects of PCP at different doses
| 2–5 mg (Stage I) | Unpredictable, drunk, euphoric, disoriented, combativeness, rage obscenity. |
| Alternating periods of lethargy and fearful agitation: waxing and waning. | |
| Decreased but intact pain perception, midpoint pupils, nystagmus, ataxia differentiates PCP from stimulants. | |
| 5–25 mg (Stage II) | Stupor, mild coma, intact response to deep pain, muscle contractions, bizarre postures. |
| More than 25 mg (Stage III) | Comatose with no response to deep pain, hyperthermia, convulsions, death. |
Modified after Milhorn HT (Milhorn, 1991 #7) and Williams and Keyes (Williams, 2001 #16)